{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:01:50Z","timestamp":1648864910725},"reference-count":3,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.neurol.2011.09.013","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T02:03:55Z","timestamp":1330999435000},"page":"464-465","source":"Crossref","is-referenced-by-count":0,"title":["Paralysie des cordes vocales secondaire \u00e0 la vincristine"],"prefix":"10.1016","volume":"168","author":[{"given":"H.","family":"Nafil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mahmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2011.09.013_bib0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1345\/aph.19396","article-title":"Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy","volume":"34","author":"Moudgil","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2011.09.013_bib0010","first-page":"583","article-title":"Low-dose vincristine-associated bilateral vocal cord paralysis","volume":"63","author":"Ryan","year":"1999","journal-title":"Conn Med"},{"key":"10.1016\/j.neurol.2011.09.013_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0305-7372(94)90027-2","article-title":"Neurotoxicity secondary to antineoplastic drugs","volume":"20","author":"Tuxen","year":"1994","journal-title":"Cancer Treat Rev"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378712006170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378712006170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T14:26:20Z","timestamp":1543155980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378712006170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":3,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0035378712006170"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2011.09.013","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}